Gastroenterology in September 2026: SPY003 phase 2 data in UC, antifungal therapy in IBD, and EPI prevalence in chronic pancreatitis.
News|Videos|April 6, 2026
5 Gastroenterology Headlines You Missed in March 2026
Author(s)Abigail Brooks, MA
Fact checked by: Victoria Johnson
Catch up on new IBD drug trial data, updated HE guidelines from the American College of Gastroenterology, and more.
Advertisement
Advertisement
March brought a steady stream of clinically significant updates in gastroenterology, spanning advances in inflammatory bowel disease (IBD), colorectal cancer screening, hepatic encephalopathy guidance, and persistent diagnostic challenges in everyday practice. From new clinical trial data to updated guideline recommendations, the month reflected both meaningful progress and ongoing gaps across the GI landscape.
Related to this article
Florence Schleich, MD, PhD, explains how exacerbation phenotypes and useful biomarkers shift across anti-IL-5, anti-IL-5R, and anti-TSLP therapies.
Strong recommendations cover carvedilol or banding for varices, semiannual HCC surveillance, vaccines, and smoking cessation.
Catch up on key FDA approvals, major trial updates, and critical clinician insights from the last 3 months.
Catch up on key FDA approvals, major trial updates, and critical clinician insights from the last 3 months.
Catch up on key FDA approvals, major trial updates, and critical clinician insights from the last 30 days.
New ARCADIA and OLYMPIA LTE data show nemolizumab sustained skin clearance and itch relief for up to 3 years in atopic dermatitis and prurigo nodularis.
Two-year ICONIC-LEAD data show oral icotrokinra sustained PASI 90 and IGA 0/1 responses in more than 70% of adults and adolescents with plaque psoriasis.
Advertisement
Advertisement